Drug Coverage In The Pandemic: US Payers Shift Focus From Costs To Access, For Now
Payer concessions to ensure access to drugs during the COVID-19 outbreak offer a benefit to patients and biopharma. But the costs involved could intensify future efforts to manage drug spending.
You may also be interested in...
CVS Caremark's Lotvin reports increased US payer interest in more comprehensive drug management solutions and that some payers are asking about dropping coverage for drug categories.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
Temporary policy may open door to longer term change as Medicare allows reimbursement of at-home administration of non-hospital drugs covered by Part B under a recently-released regulation aiding at encouraging telehealth during the coronavirus outbreak.